Effects of KATPchannel blockade by glibenclamide on the warm-up phenomenon

Tomai, Fabrizio; Danesi, Alessandro; Ghini, Anna S.; Crea, Filippo; Perino, M; Gaspardone, Achille; Ruggeri, Giulia; Chiariello, Luigi; Gioffrè, Pier Agostino

doi:10.1053/euhj.1998.1311

Cited by 61 publications

(39 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, bamiphylline, a selective antagonist of A 1 adenosine receptors, at a dose previously shown to block adaptation to ischemia during coronary angioplasty, 20 failed to prevent the warm-up phenomenon. 31 The involvement of K ATP channels in the warm-up phenomenon is uncertain. In fact, K ATP channel blockade by glibenclamide, given in the attempt to prevent the warm-up phenomenon at a dose previously shown to block adaptation to ischemia during coronary angioplasty, 18 has yielded conflicting results.…”

Section: Mechanisms Of Ischemic Preconditioningmentioning

confidence: 99%

Ischemic Preconditioning in Humans

et al. 1999

View full text Add to dashboard Cite

Abstract-Ischemic preconditioning, a powerful form of endogenous protection against myocardial infarction, has been demonstrated in several animal species and, recently, in isolated human cardiomyocytes. For both logistic and ethical reasons, no clinical study can meet the strict conditions of experimental studies on preconditioning with infarct size as the end-point. Nevertheless, the demonstration of adaptation to ischemia observed during in vitro studies on human atrial trabeculae, in patients in the setting of coronary bypass surgery, and in the setting of coronary angioplasty in the absence of collateral vessel recruitment strongly suggests that ischemic preconditioning occurs in humans. This notion is further supported by the observation that in these human models, the adaptation to ischemia is influenced by drugs acting on K ATP channels and on purinergic and ␣-adrenergic receptors, similar to what is observed in accepted experimental models of ischemic preconditioning. This important form of myocardial endogenous protection may also play a role in the warm-up phenomenon and in mediating the beneficial effects of preinfarction angina. The demonstration of ischemic preconditioning in humans and the identification of some of its mediators suggests that in patients at high risk for myocardial infarction, drugs known to block this endogenous form of protection should be used with caution, whereas drugs known to elicit preconditioning might have a relevant therapeutic role. (Circulation. 1999;100:559-563.)

show abstract

Section: Mechanisms Of Ischemic Preconditioningmentioning

confidence: 99%

Ischemic Preconditioning in Humans

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Although many authors consider that improvement of T-1.0 mm in the second test is an expression of IPC [13][14][15][16]19,20,21,31 , the minimum improvement difference is yet to be defined.…”

Section: Discussionmentioning

confidence: 99%

“…By blocking K-ATP channels of beta-pancreatic cells, sulfonylureas and glinides can also act in myocardial K-ATP channels suppressing IPC 3,[13][14][15][16][17][18] . For suppressing this phenomenon of myocardial protection, the repaglinide action is assumed as deleterious, with a potential harmful effect on the myocardium in face of ischemic events.…”

Section: Figure 1 -Correlation Analysis Between the T-10 MM (Index Omentioning

confidence: 99%

See 1 more Smart Citation

Escore eletrocardiográfico: aplicação em ergometria para avaliação do precondicionamento isquêmico

Uchida

Moffa²,

Hueb³

et al. 2010

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…Glibenclamide has been shown to affect ischaemic preconditioning but trials have not shown beyond doubt that it is associated with increased myocardial infarction. However drugs that inhibit the K ATP channel opening, such as glibenclamide, are related to loss of ischaemic preconditioning [79][80][81] . GLP-1 receptors are found in the heart.…”

mentioning

confidence: 99%

Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors

Tomkin¹

2014

WJD

View full text Add to dashboard Cite

Core tip: Treatment of diabetes is difficult. Initial success in achieving treatment goals is followed by deterioration and the necessity for additional treatments. Exciting new drugs with new modes of action, have stimulated diabetologists to strive for improved control in the knowledge that complications will be reduced or prevented. Obese patients, who loose weight on glucagon-like peptide-1 agonists are usually delighted with these drugs but for those who fail to loose weight changing to oral dipeptidyl peptidase-4 inhibitors would seem a good choice. sodium-glucose transporter-2 inhibitors have the added benefit of being effective even if blood sugar is near to target but uro-genital infection is a concern.Tomkin GH. Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors. World J Diabetes 2014; 5(5): 636-650 Available from: URL: http://www.wjgnet.com/1948-9358/full/ v5/i5/636.htm DOI: http://dx.doi.org/10. 4239/wjd.v5.i5.636 INTRODUCTIONReaders interested in diabetes must be sick and tired reading that diabetes is a global problem of immense size and getting worse by the day with predictions that we will all have the disease one day! I exaggerate of course but it is sad to realise that although we know so much more about the condition we have made little progress in reducing or conquering the disease. A recent history of diabetes in the past 200 years by Polonsky [1] gives an excellent review of the history of discovery of so many mechanisms that are faulty in diabetes and the number of Nobel prize winners who have contributed to such wonderful success, yet more and more people are being diagnosed with the condition/disease and the consequences are immense in terms of suffering and financial cost. One should not forget that before the discovery of insulin 90 years ago AbstractIn recent years the treatment focus for type 2 diabetes has shifted to prevention by lifestyle change and to more aggressive reduction of blood sugars during the early stage of treatment. Weight reduction is an important goal for many people with type 2 diabetes. Bariatric surgery is no longer considered a last resort treatment. Glucagon-like peptide-1 agonists given by injection are emerging as a useful treatment since they not only lower blood sugar but are associated with a modest weight reduction. The role of the oral dipeptidyl peptidase 4 inhibitors is emerging as second line treatment ahead of sulphonylureas due to a possible beneficial effect on the beta cell and weight neutrality. Drugs which inhibit glucose re-absorption in the kidney, sodium/glucose co-transport 2 inhibitors, may have a role in the treatment of diabetes. Insulin treatment still remains the cornerstone of treatment in many patients with type 2 diabetes.© 2014 Baishideng Publishing Group Inc. All rights reserved. 636October 15, 2014|Volume 5|Issue 5| WJD|www.wjgnet.com diabetes was a rapidly fatal disease and there was little interest in what we now term type 2 diabetes. Type 2 diabetes now makes up 90% of all diabetes. Insulin resist...

show abstract

Effects of KATPchannel blockade by glibenclamide on the warm-up phenomenon

Cited by 61 publications

References 21 publications

Ischemic Preconditioning in Humans

Ischemic Preconditioning in Humans

Escore eletrocardiográfico: aplicação em ergometria para avaliação do precondicionamento isquêmico

Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors

Contact Info

Product

Resources

About